Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to a significant stock price decline after the company announced disappointing clinical trial results [3][4]. Group 1: Allegations and Impact - The lawsuit claims that aTyr Pharma provided overly positive statements about Efzofitimod while concealing material adverse facts about the drug's efficacy, particularly its ability to allow patients to taper steroid usage completely [3]. - The truth about the drug's performance was revealed on September 15, 2025, when aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically regarding the change from baseline in mean daily OSC dose at week 48 [3]. - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking a decline of 83.2% in just one day [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as January 16, 2025, to September 12, 2025, and shareholders are encouraged to register for potential lead plaintiff appointment [3][4]. - The deadline for shareholders to seek lead plaintiff status is December 8, 2025, and there is no cost or obligation to participate in the case [4]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [4]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [5]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that artificially inflated stock prices [5].

Core Viewpoint - Glancy Prongay & Murray LLP has initiated an investigation into aTyr Pharma Inc. regarding potential violations of federal securities laws, indicating possible legal challenges for the company and its investors [1]. Company Summary - aTyr Pharma Inc. is under scrutiny for its compliance with federal securities laws, which may affect investor confidence and the company's market performance [1]. - The investigation was announced following a significant event on September 15, which has not been detailed in the provided content but suggests a triggering incident for the inquiry [1].

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of aTyr Pharma Inc. ("aTyr†or the "Company†) (NASDAQ: ATYR) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ATYR PHARMA INC. (ATYR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at h. ...

Core Viewpoint - aTyr Pharma, Inc. is facing a class action lawsuit from investors who purchased securities during the specified class period, following the announcement of disappointing clinical trial results [1][3]. Group 1: Legal Action - The Portnoy Law Firm is advising aTyr Pharma investors regarding a class action lawsuit for those who bought securities between January 16, 2025, and September 12, 2025 [1]. - Investors have until December 8, 2025, to file a lead plaintiff motion in the class action [1]. Group 2: Clinical Trial Results - On September 15, 2025, aTyr announced topline results from the Phase 3 EFZO-FIT™ study involving 268 patients with pulmonary sarcoidosis, which failed to meet its primary endpoint [3]. - Following the announcement of the trial results, aTyr's stock price experienced a significant decline during intraday trading on the same day [3]. Group 3: Investor Support - The Portnoy Law Firm offers complimentary case evaluations for investors to discuss their legal rights and options for recovering losses [2]. - The firm has a history of recovering over $5.5 billion for investors affected by corporate wrongdoing [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against ATyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [4][6]. Group 1: Legal Investigation - The firm is reminding investors of the December 9, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against ATyr Pharma [4]. - The complaint alleges that ATyr and its executives violated federal securities laws by making false and misleading statements about Efzofitimod, particularly regarding its ability to allow patients to taper off steroids [6]. Group 2: Drug Efficacy and Market Impact - In the EFZO-FIT study, Efzofitimod did not demonstrate a significant change in mean daily oral corticosteroid (OCS) dose at week 48, with a reduction of 2.79 mg for the drug compared to 3.52 mg for placebo [7]. - Complete steroid withdrawal was achieved in 52.6% of patients treated with Efzofitimod versus 40.2% on placebo [7]. - Following the release of the study results, ATyr's stock plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [7].

Shareholders who purchased shares of ATYR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/atyr-pharma-inc-loss-submission-form/?id=172042&from=4 CLASS PERIOD: January 16, 2025 to September 12, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of aTyr Pharma Inc. ("aTyr†or the "Company†) (NASDAQ: ATYR) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ATYR PHARMA INC. (ATYR), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On September 15, 2025, aTyr announced that the Phase 3 study of its intrav. ...

Core Points - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of aTyr Pharma, Inc. common stock between January 16, 2025, and September 12, 2025 [1] - The lawsuit claims that aTyr Pharma made false and misleading statements regarding the efficacy of its drug Efzofitimod, particularly concerning its ability to allow patients to taper steroid usage [5] Group 1 - The class action lawsuit allows investors who purchased aTyr Pharma common stock during the specified period to seek compensation without any out-of-pocket fees through a contingency fee arrangement [2] - Investors interested in serving as lead plaintiff must file a motion with the Court by December 8, 2025 [1][3] - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4] Group 2 - The complaint alleges that aTyr Pharma provided overwhelmingly positive statements while concealing material adverse facts about the drug's efficacy, leading to investor damages when the truth was revealed [5] - No class has been certified yet, meaning investors are not represented by counsel unless they retain one [7]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against aTyr Pharma, Inc. due to allegations of misleading statements regarding the efficacy of its drug Efzofitimod, which led to significant financial losses for investors [1][3]. Company Overview - aTyr Pharma, Inc. is a biopharmaceutical company whose stock has recently experienced a dramatic decline following the release of clinical trial results for Efzofitimod [1][4]. Legal Proceedings - A federal securities class action has been filed against aTyr, with a deadline of December 9, 2025, for investors to seek the role of lead plaintiff [1][5]. - The complaint alleges that aTyr and its executives violated federal securities laws by making false and misleading statements about the drug's capabilities [3][4]. Clinical Trial Results - In the EFZO-FIT study, Efzofitimod did not demonstrate a significant reduction in mean daily oral corticosteroid (OCS) dose compared to placebo, with a reduction of 2.79 mg for the drug versus 3.52 mg for placebo [4]. - Complete steroid withdrawal was achieved in 52.6% of patients treated with Efzofitimod compared to 40.2% on placebo [4]. Stock Performance - Following the release of the clinical trial results, aTyr's stock plummeted by 83.25%, dropping from a market close of $6.03 on September 12 to $1.01 on September 15 [4].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In aTyr (ATYR) To Contact Him Directly To Discuss Their Options If you purchased or acquired aTyr common stock between January 16, 2025, and September 12, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bra ...